Kbi-110 Repack -

Then, at the bottom, isolated in a locked partition, was a single file named:

| Phase | Indication | Design (as of 2024) | Key Endpoints | |-------|------------|----------------------|---------------| | | Relapsed/Refractory AML | 3 + 3 dose‑escalation; 40 mg‑200 mg QD oral; expansion cohort at RP2D | Safety, PK/PD, reduction in peripheral blasts, BRD9‑target engagement (PBMC ChIP‑seq) | | Phase I/II (parallel) | Idiopathic Pulmonary Fibrosis | Randomized, double‑blind, placebo‑controlled; 12‑week treatment | Change in forced vital capacity (FVC), HRCT fibrosis score, biomarker panel (MMP‑7, CCL‑18) | | Pre‑IND (pre‑clinical) | ALS | IND‑enabling toxicology & GLP PK studies | N/A | KBI-110

To understand the value of KBI-110, one must understand the enemy it fights. Polymers, particularly polyolefins like polypropylene and polyethylene, are inherently susceptible to environmental attack. Then, at the bottom, isolated in a locked